Search research articles
Contact Us
Filters
Showing results (291-300 of 302) with videos related to
Page
of 31
Sort By:
The Journal of Experimental Medicine
|
April 14, 2021
Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia
Joseph E Rupert, Ashok Narasimhan, Daenique H A Jengelley, et al.
Annals of Surgery
|
August 26, 2011
Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma?
Leonidas G Koniaris, David M Levi, Felipe E Pedroso, et al.
Frontiers in Physiology
|
January 27, 2017
Differential Bone Loss in Mouse Models of Colon Cancer Cachexia
Andrea Bonetto, Joshua K Kays, Valorie A Parker, et al.
Breast Cancer Research and Treatment
|
December 6, 2011
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
A J Montero, C M Diaz-Montero, Y E Deutsch, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
July 10, 2019
The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy
Xiaoling Zhong, Marianne Pons, Christophe Poirier, et al.
Plos One
|
June 16, 2025
Transcriptomic profiling of pancreatic neuroendocrine tumors: dysregulation of WNT, MAPK, PI3K, neddylation pathways and potential non-invasive biomarkers
Helvijs Niedra, Olesja Rogoza, Rihards Saksis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2025
Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
Inna M Chen, Julia S Johansen, Susann Theile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2025
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
Inna M Chen, Julia S Johansen, Susann Theile, et al.
Neuron
|
October 6, 2022
A brain atlas of synapse protein lifetime across the mouse lifespan
Edita Bulovaite, Zhen Qiu, Maximilian Kratschke, et al.
Cancer Letters
|
September 17, 2025
Aurora kinase A inhibition as a synthetic lethality strategy in ARID1A-mutated gastroenteropancreatic neuroendocrine carcinoma
Maria Urbanova, Fabrice Viol, Laura Ruiz-Cañas, et al.
Page
of 31
Search research articles
Search
Showing results (291-300 of 302) with videos related to
Sort By:
Page
of 31
The Journal of Experimental Medicine
|
April 14, 2021
Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia
Joseph E Rupert, Ashok Narasimhan, Daenique H A Jengelley, et al.
Annals of Surgery
|
August 26, 2011
Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma?
Leonidas G Koniaris, David M Levi, Felipe E Pedroso, et al.
Frontiers in Physiology
|
January 27, 2017
Differential Bone Loss in Mouse Models of Colon Cancer Cachexia
Andrea Bonetto, Joshua K Kays, Valorie A Parker, et al.
Breast Cancer Research and Treatment
|
December 6, 2011
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
A J Montero, C M Diaz-Montero, Y E Deutsch, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
July 10, 2019
The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy
Xiaoling Zhong, Marianne Pons, Christophe Poirier, et al.
Plos One
|
June 16, 2025
Transcriptomic profiling of pancreatic neuroendocrine tumors: dysregulation of WNT, MAPK, PI3K, neddylation pathways and potential non-invasive biomarkers
Helvijs Niedra, Olesja Rogoza, Rihards Saksis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2025
Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
Inna M Chen, Julia S Johansen, Susann Theile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2025
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
Inna M Chen, Julia S Johansen, Susann Theile, et al.
Neuron
|
October 6, 2022
A brain atlas of synapse protein lifetime across the mouse lifespan
Edita Bulovaite, Zhen Qiu, Maximilian Kratschke, et al.
Cancer Letters
|
September 17, 2025
Aurora kinase A inhibition as a synthetic lethality strategy in ARID1A-mutated gastroenteropancreatic neuroendocrine carcinoma
Maria Urbanova, Fabrice Viol, Laura Ruiz-Cañas, et al.
Page
of 31